The vagus nerve has an unexpected connection to headache disorders — unexpected because headache pain is primarily transmitted through the trigeminal nerve, not the vagus. Yet vagus nerve stimulation is now FDA-cleared for both migraine and cluster headache, and the neuroanatomical reasons for its effectiveness reveal how deeply the vagal and trigeminal systems are intertwined in the brainstem.
Where Vagus Meets Trigeminal
The trigeminal nerve (cranial nerve V) carries pain signals from the face, head, and meninges. The vagus nerve (cranial nerve X) carries sensory information from the throat, chest, and abdomen. These two nerves should operate independently, but they converge at a critical brainstem relay: the spinal trigeminal nucleus, specifically its caudal subdivision (the trigeminocervical complex). Vagal afferents from the upper cervical region and the dura mater project to this same nucleus, creating an overlap zone where vagal input can modulate trigeminal pain processing.
This convergence explains several clinical observations. It explains why throat or neck problems can trigger headaches (cervicogenic headache involves C1-C3 afferents converging with trigeminal fibres). It explains why nausea accompanies migraine (the vagal emetic pathway is activated alongside the trigeminal pain pathway). And it explains why stimulating the vagus nerve can reduce headache pain — vagal input to the trigeminocervical complex can inhibit trigeminal nociceptive transmission through descending modulation.
gammaCore: FDA-Cleared Vagal Headache Treatment
The most direct clinical evidence for the vagus-headache connection comes from gammaCore, a handheld non-invasive vagus nerve stimulation (nVNS) device manufactured by electroCore. Applied to the cervical vagus nerve on the neck, it delivers mild electrical stimulation through the skin in 120-second treatment cycles.
gammaCore holds FDA clearances for three headache indications:
Acute migraine treatment. The PRESTO trial, a multicentre, randomised, double-blind, sham-controlled study published in Neurology in 2019, demonstrated that nVNS was significantly more effective than sham stimulation in achieving pain freedom at two hours for episodic migraine attacks. Pain-free rates were modest (about 30 percent versus 20 percent for sham), but notably without the cardiovascular restrictions that limit triptan use.
Migraine prevention. The PREMIUM trial found that daily prophylactic nVNS reduced migraine days per month compared with sham, with the effect becoming more pronounced over the 12-week treatment period. This suggests a cumulative neuromodulatory effect rather than simple acute pain relief.
Episodic cluster headache. The ACT1 trial showed that nVNS significantly reduced attack severity and duration in episodic cluster headache, one of the most painful conditions in medicine. The effect was less clear in chronic cluster headache (ACT2 trial), suggesting that the vagal mechanism may be more effective for the episodic pattern where autonomic cycling is more prominent.
Your local vagus nerve experts
Find a vagus nerve practitioner near you
Our directory lists 2,685 practitioners across the US, from polyvagal-informed therapists to HRV biofeedback clinics.
Or browse by approach
The directory covers the United States for now. Listings come from practitioners’ own websites and are not endorsements or medical advice. Browse the full directory.
How Vagal Stimulation Reduces Headache Pain
The mechanism by which cervical VNS reduces headache pain involves several pathways operating simultaneously.
Trigeminal nucleus inhibition. Vagal afferent input to the spinal trigeminal nucleus activates inhibitory interneurons that suppress nociceptive (pain) signal transmission. Animal studies have shown that VNS directly reduces neuronal firing rates in the trigeminocervical complex in response to dural stimulation.
Descending pain modulation. Vagal stimulation activates the locus coeruleus and periaqueductal grey, two brainstem structures that send descending inhibitory projections to spinal and trigeminal pain pathways. This is the same noradrenergic and serotonergic pain-modulation system targeted by some preventive migraine medications.
CGRP reduction. Calcitonin gene-related peptide (CGRP) is the key neuropeptide in migraine pathophysiology — its release from trigeminal nerve terminals causes meningeal vasodilation and neurogenic inflammation. The new generation of migraine drugs (gepants and anti-CGRP monoclonal antibodies) specifically target this pathway. Preclinical research shows that VNS reduces CGRP release from trigeminal neurons, providing a drug-free approach to the same molecular target.
Cortical spreading depression suppression. Cortical spreading depression (CSD) — a wave of neuronal depolarisation that sweeps across the cortex — is believed to underlie migraine aura and may trigger the headache phase itself. Animal studies from 2019 demonstrated that VNS suppressed CSD propagation, which may explain both the acute and preventive effects of nVNS in migraine.
Cluster Headache: The Vagal Autonomic Connection
Cluster headache belongs to a group called trigeminal autonomic cephalalgias (TACs), and the “autonomic” component is partly vagal. During a cluster attack, parasympathetic activation produces ipsilateral tearing, nasal congestion, eyelid drooping, and facial sweating — signs of vagal and other parasympathetic outflow through the sphenopalatine ganglion. The attacks follow a circadian and circannual pattern linked to hypothalamic cycling, and the hypothalamus receives direct vagal input.
VNS may help cluster headache by modulating the trigeminal-autonomic reflex arc — the feedback loop between trigeminal pain afferents and parasympathetic efferents that amplifies both pain and autonomic symptoms during an attack. By dampening vagal efferent over-activity while simultaneously inhibiting trigeminal nociception, nVNS can interrupt this self-reinforcing cycle.
Vagal Dysfunction as a Headache Risk Factor
Beyond direct stimulation therapy, there is growing evidence that chronic vagal underactivity contributes to headache susceptibility. Migraine patients as a group show lower resting HRV compared with headache-free controls, and HRV drops further in the 24 to 48 hours preceding a migraine attack. This pre-ictal autonomic shift — reduced parasympathetic (vagal) tone with rising sympathetic activity — may represent a window of vulnerability that lowers the threshold for CSD or trigeminal activation.
This has practical implications. Interventions that build vagal tone over time — regular exercise, HRV biofeedback, breathing practices with extended exhalation — may function as migraine prevention by raising the threshold for attacks. Several small trials of HRV biofeedback for migraine prevention have shown promising results, with reductions in attack frequency comparable to some prophylactic medications.
Cervicogenic Headache and Vagal Compression
Cervicogenic headache — pain referred to the head from structures in the upper cervical spine — involves the same trigeminocervical convergence zone where vagal and trigeminal afferents meet. Degenerative changes, disc pathology, or postural dysfunction at C1-C3 can irritate both vagal and upper cervical nerve roots, producing a headache with accompanying vagal symptoms: nausea, lightheadedness, or a sensation of fullness in the ear.
This overlap explains why cervicogenic headache is frequently misdiagnosed as migraine — both involve pain referred to the temporal or frontal region and both can include nausea and photophobia. The distinguishing features are typically mechanical: cervicogenic headache worsens with specific neck positions or sustained postures and improves with cervical mobilisation, while migraine follows its own internal timing.
Practical Takeaways
For anyone with frequent headaches, vagal health is worth considering as part of a management strategy. gammaCore is available by prescription for migraine and cluster headache and can be used alongside conventional medications without the drug interactions or cardiovascular restrictions of triptans. Building baseline vagal tone through daily practices (extended-exhale breathing, regular aerobic exercise, adequate sleep) may reduce headache frequency by raising the autonomic threshold for attacks. And for headaches with prominent neck involvement or accompanying nausea and lightheadedness, evaluating the cervical spine and vagal function may reveal a treatable mechanical component.
Headache disorders are just one of many conditions connected to the vagus nerve’s vast regulatory network. For a comprehensive guide to this nerve and evidence-based strategies for supporting it, get the Vagus Nerve & Me eBook.
